Abstract Mapping functions are estimated using regression analyses and are frequently used to predict health state utility values (HSUVs) in decision analytic models. Mapping functions are used when evidence on the required preference-based measure (PBM) is not available, or where modelled values are required for a decision analytic model, for example to control for important sociodemographic variables (such as age or gender). This article provides an overview of the latest recommendations including premapping considerations, the mapping process including data requirements for undertaking the estimation of mapping functions, regression models for estimating mapping functions, assessing performance and reporting standards for mapping studies. Examples in rheumatoid arthritis are used for illustration. When reporting the results of mapping standards the following should be reported: a description of the dataset used (including distributions of variables used) and any analysis used to inform the selection of the model type and model specification. The regression method and specification should be justified, and as summary statistics may mask systematic bias in errors, plots comparing observed and predicted HSUVs. The final model (coefficients, error term(s), variance and covariance) should be reported together with a worked example. It is important to ensure that good practice is followed as any mapping functions will only be as appropriate and accurate as the method used to obtain them; for example, mapping should not be used if there is no overlap between the explanatory and target variables.
Mapping is typically used to predict required or 'target' health state utility values (HSUVs) and are often used when the required evidence is not available or to link the target HSUV measure to other health-related quality of life (HRQOL) or clinical 'source' measures.
It is important to ensure that appropriate analysis is undertaken prior to estimating regressions, and that appropriate regression models, model specifications and datasets are used together with how and where the predicted HSUVs will be used, as this can inform the selection of the most appropriate mapping function.
Mapping is inappropriate and will not produce accurate results if (a) there is little conceptual overlap between source and target measures, (b) the target or source measure is inappropriate in the population of interest, (c) the estimation data has not been modelled using appropriate models and model specifications or (d) the estimation sample data is unrepresentative of the target sample data it will be applied to.
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Introduction
The practice of fitting a statistical regression model to data involving measures of health-related quality of life (HRQOL) is referred to as 'mapping' or 'cross-walking' in the literature. Mapping functions are frequently used to predict health state utility values (HSUVs) in decision analytic models. The mapping functions are obtained using regression analysis, a statistical process used to estimate relationships between variables. In its simplest form, the mapping function (sometimes referred to as an 'algorithm') obtained from the regression will take the form of
whereby
• y is the dependent variable (the target being predicted), • x is the vector of explanatory variables (sometimes called independent variables or predictors), • b n are the coefficients obtained from the regression analysis, • and e is the residual (error term), with i indexing the patient.
Mapping functions are used to predict HSUVs in the following cases:
• when the required preference-based measure (PBM) is not included in the dataset of interest; • to generate HSUVs for a decision analytic model where modelled values are required (e.g. when sample size is small) to control for important sociodemographic characteristics (e.g. age or gender) or when existing evidence is limited (e.g. for severe health states).
The regression analysis may be undertaken using evidence from the clinical trial of interest or may require access to a separate external dataset. Instances when external datasets are required include when the clinical trial of interest does not collect the required PBM or the evidence collected is limited in ability to inform all health states within the decision analytic model (e.g. does not include patients across the full spectrum of disease severity, or the sample size or numbers of observed clinical events are too small to subgroup for the health states in the decision analytic model) [1] . It is recommended that any mapping exercise is conducted on empirical data [2] .
This paper provides an overview of the pre-mapping considerations, the mapping process including data requirements for undertaking the estimation of mapping functions, regression models for estimating mapping functions, assessing performance and reporting standards for mapping studies. A case study using published evidence on the relationship between a clinical measure of severity (the Health Assessment Questionnaire [HAQ] ) and EQ-5D in rheumatoid arthritis is used as an exemplar throughout (see Box 1 and the online Appendix Table A1 ) in the electronic supplementary material for additional information on the rheumatoid arthritis mapping examples used).
Pre-mapping Considerations
Prior to commencing mapping it is important to consider where the mapping functions will be applied. When the function is to be used in a decision model, it is important to identify,
• the required PBM (generally informed by the requirements of the reimbursement agency); • the health state definitions for the decision analytic model (e.g. health states representing discrete clinical events, health states defined by a clinical measure(s) of severity); • the distribution of patient characteristics (e.g. age, condition and condition severity range); • the intervention and comparator(s) under evaluation (are these likely to have an independent effect on HRQOL?), and the decision analytic model structure (cohort, individual patient simulation). Figure 1a , b outline the process used to identify if a mapping function is required to predict the HSUVs for a decision model. The first example, Fig. 1a , has discrete health states which are defined using clinical events, such Box 1 Example of a linear function used to explore the relationship between the Health Assessment Questionnaire (HAQ) and EQ-5D
Example 1
A simple linear function was obtained using ordinary least square regressions to provide a relationship between the HAQ and EQ-5D in patients with rheumatoid arthritis [16] . The HAQ ranges from 0 (no disability) to 3 (completely disabled) and EQ-5D ranges from 1 (full health) to -0.59 (worst possible health state). Consequently, we would expect any relationship between the two measures to be negative; that is, as HAQ increases, EQ-5D decreases:
EQ-5D = 0.86 0:20 HAQ);
The beta coefficient for HAQ (i.e. -0.20) indicates that for every unit increase in HAQ, EQ-5D reduces by 0.20 units, as expected. This relationship is statistically significant at the p < 0.05 level.
*Next steps once the HSUVs have been selected/predicted
Irrespective of whether HRQoL evidence from the clinical trial is used, appropriate SRs should be conducted either to identify the required HSUVs or the required mapping studies. The results of the SRs should be reported in detail and the final choice of HSUVs / mapping function used in the DM justified. Any appropriate HSUVs /mapping functions from SRs that are not used in the DM should be compared with those used, and SA should be conducted to illustrate the effect on the ICER.
No
A decision model is required to explore the cost-effectiveness of Drug X in Condition Y.
The output from the model is to be in the form of cost per QALY, and the reimbursement authority agency states a preference for a specific PBM (target PBM). If evidence from the required PBM is not available in the clinical trial of interest, then there are two options. The first, and typically preferred option, is to conduct a systematic review of the literature to identify HSUVs using the required PBM, see Ara et al. [3] for guidance on this. The second option, if another HRQOL measure is available in the clinical trial of interest, is to conduct a systematic review of the mapping literature to identify validated and appropriate mapping studies (mapping from the HRQOL measure included in the study to the required PBM) [3] . Where no validated and appropriate mapping functions are identified, an external dataset that includes evidence from both the HRQOL measure included in the clinical trial and the required PBM can be used to generate a new mapping function. If no other HRQOL measure has been included, then an independent study may need to be undertaken to A decision model is required to explore the cost-effectiveness of Drug X in Condition Y.
The output from the model is to be in the form of cost per QALY, and the reimbursement authority agency states a preference for a specific PBM (target PBM).
The decision model uses a series of continuous health states to represent the progression of disease. The HS are defined by the clinical variable used to represent the effectiveness of the intervention.
Conduct mapping study on data from clinical trial (from clinical variable to target PBM)
Use mapping function to predict HSUVs in DM*
Use mapping function(s) identified in SR to predict HSUVs in DM*
Conduct an independent regression analysis / mapping function in an external dataset 
Overview of the Mapping Process
Mapping involves four key stages:
1. Identifying an appropriate estimation dataset. 2. Applying regression techniques to find the best-fit statistical relationship between the measures (either mapping to the index score or the classification system of the target PBM). This stage includes the refinement of the model specifications, the selection of the model type, and assessing the model performance. 3. Applying the regression results to the study dataset of interest to predict HSUVs. 4. Assessing/validating the regression results (through a thorough comparison of predicted and observed HSUVs, comparison with any evidence in the literature, and applying the mapping function in a second dataset which satisfies all the conditions of Step 1.
(NB: it is rare that the latter is conducted due to lack of availability of appropriate evidence.)
It is worth noting that regression results can be applied to aggregate values rather than individual levels to produce predictions, such as using summary data published in a paper [14] .
Data Requirements for Undertaking Mapping
The use of a published appropriate mapping function requires access to individual patient-level evidence on the explanatory variables used in the mapping function. Where an external estimation dataset is used, all explanatory variables should be in both datasets. The clinical and demographic characteristics, and the distribution of the explanatory variables, should also be similar in both datasets as the statistical relationship may differ at different severities of health [5] . Primary data collection is required if no appropriate estimation dataset exists. There are a number of basic analyses that should be conducted prior to estimating a mapping function (Box 2) [1].
Explanatory and Target Preference-Based Measure (PBM) Variables
The vast majority of mapping functions tend to use HSUVs (i.e. the preference-based index used to estimate quality-adjusted life-years [QALYs]) as the dependent variable. For the UK EQ-5D-3L measure this would be the HSUVs that range from 1 (representing no problem on any of the five dimensions) to -0.59 (representing extreme problems on all five dimensions). The usefulness of functions obtained using the preference-based index as the dependent variable is constrained to the setting of the preference weights used. For example, a function obtained using the UK EQ-5D-3L preference weights cannot be used to generate EQ-5D-3L HSUVs suitable for the Netherlands (which have their own set of preference weights for the EQ-5D). An approach that can be used to predict HSUVs for alternative sets of preference weights is known as 'response mapping' [6] . Again using the EQ-5D-3L as an example, response mapping uses logistic regressions (one regression for each dimension) and the responses to the dimension questions Box 2 Summary of recommendations before estimating mapping functions. Adapted from Wailoo et al. [ 1] Required application of the mapping function
• Determine the range of health states that require utility estimates for the cost-effectiveness model and any important covariates.
• Ensure the patient characteristics in the dataset used to estimate the mapping function match those of the proposed cost-effectiveness model, in particular the extremes of disease severity in chronic conditions, or time since event for acute clinical events. If more than one dataset is available, their characteristics should be compared to justify the final dataset choice.
• Determine whether a mapping function obtained using statistical regression methods is required, or if mean values from subgroups of patients will suffice.
Relationships between explanatory and independent variables
• Examine the characteristics (dispersion, distribution, atypical values, etc.) of both the explanatory and dependent variables, including the level of overlap or relationship between the variables. • Identify whether the relationship between the explanatory and dependent variables is likely to be influenced by any intervention the patient will receive.
(as opposed to the preference-based index) as the dependent variables [7] . The predicted values from the logistic models (five models predicting the probability of scoring 1, 2 or 3 on the five dimensions) are then used together with the required preference weights for each of these responses to predict the associated EQ-5D HSUV. Interested readers are pointed to Ara et al. [7] for a worked example. The choice of both the dependent and explanatory variables will be informed by the evidence available in the datasets used for mapping, and where the mapping function will be applied. For example, if the mapping function is to be used in a decision analytic model that will be adapted to inform policy decisions in multinational settings, response mapping avoids the need to obtain different mapping functions for each required set of preference weights.
Prior knowledge as well as standard techniques should be used to examine the relationship between the explanatory and dependent variables to inform choice of model specification including the inclusion of interaction or squared terms (example provided in Box 3).
It is important that both the required PBM and any measure of HRQOL used as an explanatory variable (e.g. an alternative generic preference-based measure [GPBM] or condition-specific measure [CSM] ) are valid for use in the population where they are being applied. If either measure is not appropriate (i.e. not relevant or insensitive) for the condition of interest, then mapping between the measures is also inappropriate [10] . It is also important that there is conceptual (i.e. they are measuring similar concepts or dimensions as shown using a comparison of the conceptual domains of each measure) and empirical (i.e. they are correlated) overlap between the dependent and explanatory measures. The mapping function will not produce accurate predictions of HSUVs if there is little overlap, and the model may suffer from omitted variable bias. Evidence shows that this is more likely when mapping from CSMs to GPBMs. One example where there was little overlap was mapping the overactive bladder questionnaire onto the SF-6D [10] , potentially suggesting that the generic measure was insensitive in this patient group. If this occurs, a better solution may be to consider a condition-specific preference-based measure (Fig. 2) .
Sample size considerations also apply; for example, item-level dummy models for explanatory measures with many items may not be appropriate in small datasets. In addition, sample characteristics are also important; for example, a dataset with few responses in severe health is unlikely to enable the estimation of accurate mapping functions for severe health. Summary statistics and distributions of the dependent and explanatory variables used in the mapping should be reported.
Regression Models
A range of different statistical models can be used to estimate mapping functions, and the literature exploring different approaches is increasing each year. The most Box 3 An example where additional explanatory variables are included when exploring the relationship between the Health Assessment Questionnaire (HAQ) and EQ-5D in rheumatoid arthritis (RA)
Example 2
The HAQ does not include any information on pain levels, but EQ-5D has a pain dimension. Hurst et al. explored the effect of including additional explanatory variables (including a measure of pain) [8] :
EQ-5D = 1.12 0.188 HAQ 0.008 HAD mood 0.003 Pain VAscale) 0.068 disease activity).
The beta coefficient for pain -VA (visual analogue) scale ( -0.003) was statistically significant at the p 0.05 level, and illustrates that as pain increases, EQ-5D decreases, as expected.
Relationships between measures are not always linear, and the possibility of a curved relationship between EQ-5D and HAQ was explored through the inclusion of a squared term in the analyses used to inform an RA model [9] , EQ-5D = 0.804 0.203 HAQ 0.045 HAQ 2 .
The beta coefficient for HAQ squared was statistically significant. It is clear from Fig. 2 that the relationship between EQ-5D and HAQ now changes across the indices, with a greater magnitude per unit change at more severe levels. Consequently, a change in HAQ from 3 to 2 produces a greater change in EQ-5D (EQ-5D change = -0.5226) than a change in HAQ from 1 to 0 (EQ-5D change = -0.2480). See Fig. 2 . < Fig. 2 Plot illustrating magnitude of change in EQ-5D associated with one unit change in Health Assessment Questionnaire (HAQ) [8, 16] appropriate model for use will depend on the measures involved, the distribution of the dependent variable, the relationship between the dependent and explanatory variables, any interactions between the variables and the evidence available in the datasets used. Plots of the dependent variable are particularly useful as they indicate the distribution of the data, which is informative for selection of the regression method. Box 4 provides a checklist for the steps to take when designing and choosing a model to estimate the mapping function (see Box A1, and papers by Hernandez et al. [11, 12] , for additional information and empirical examples).
When a HRQOL measure is used as an explanatory variable, mapping can be performed by modelling from the total score, the dimension scores, the item scores, or the item responses [10] .
While linear ordinary least squares (OLS) is the simplest approach and is frequently used as a starting point, this may be inappropriate for the distribution of the preferred PBM. Much of the literature has focussed upon mapping to EQ-5D and models obtained using OLS regressions have a tendency to under-predict at the top and over-predict at the bottom of the index [10] . The EQ-5D-3L distribution poses particular challenges as the data are typically bimodal or trimodal, with a large proportion of responses at 1 (full health), and peaks for moderate health states and severe health states. Tobit and censored least absolute deviation (CLAD) models have been used as a way of dealing with the large proportion of responses at 1, though these do not always offer an improvement in predictive accuracy [5] . Although the latent class mixture model, censored mixture model and multinomial logit model have all been used to model the trimodal distribution more appropriately, these models can prove difficult to estimate on smaller samples. When mapping between HRQOL measures, while the accuracy of the predicted values will be governed by the degree of content overlap to some degree, a mis-specified model will not produce the most accurate predictions.
Selecting and Applying Mapping Functions
Published appropriate mapping functions are potentially the preferred first option but it is important to review these thoroughly and justify the final choice through comparing the characteristics of the dataset used in the regression analyses to those where the function will be applied, and the reported predictive ability of the function [5] . Particular consideration should be given to potential errors if the function is to be used to predict values beyond the limits of any of the variables used in the regression analyses (this relates to both the dependent and explanatory variables). If there is sufficient evidence for the preferred PBM in the clinical study used to inform the effectiveness of the intervention in a decision model, it may be appropriate to estimate a mapping function using the evidence from the clinical study, but this will depend on why mapping is required, the quality of the evidence and the availability of alternative external datasets.
For de novo studies, the selection of the final mapping function in terms of regression model, dependent and explanatory variables, will depend on performance. Alongside predictive ability (the difference between observed and predicted HSUVs reported as mean error, root mean square error or mean absolute errors), other information such as goodness of fit, information criterion and whether regression methods assumptions are met should also be reported (see Table 1 for an explanation of statistics).
The recommended mapping function should be reported together with the statistics needed to undertake univariate and probabilistic sensitivity analyses (confidence intervals or standard errors around the betas, and the variance covariance matrix-a standard output from the regression analysis in many statistical software packages). The error term distribution is also important to reflect individuallevel variability in HSUVs. If a published mapping function is used, and the required statistics are not available to explore the variance in the predicted HSUVs, a threshold analysis can be conducted to determine the HSUVs required to ensure the results from the decision model would be considered cost effective.
An important consideration when performing mapping functions is whether the results are to be used in a cohort Box 4 Recommendations for estimating mapping functions. Adapted from Wailoo et al. [1] Summary of statistical modelling recommendations 1. Assess range and distribution of utility score (summary statistics and plot) or dimensions of explanatory variable (target preference-based measure). 2. Use the simplest regression models possible that satisfy associated assumptions considering the distribution of the target a utility score or dimensions. 3. Select explanatory variables using theory and observed relationships. Include all variables considered important as omission can risk mis-specification and biased estimates. 4. Select the final model using good practice techniques for all regression analyses, including performance and model fit.
a The target utility is the dependent variable model or an individual-level simulation. The former will require mean HSUVs, which generally tend to be in the central area of a PBM's range, while the latter is far more likely to require a much wider range of HSUVs. This is particularly important when assessing the predictive ability of the mapping function, including when sampling for probabilistic sensitivity analyses.
Reporting Standards for Mapping Studies
A summary of recommendations for reporting mapping studies from a recent ISPOR task force is provided in Box 5 and additional details are available from the MAPS [MApping onto Preference-based measures reporting Standards] statement) [13] . It is good practice to fully describe the dataset used to estimate the mapping function, including the distribution (e.g. range, mean, standard deviation) of all variables used in the regression, and any analysis used to inform the selection of the model type and model specification (see Hernandez Alava et al. [12] for a worked example). The regression method and specification should be justified, and sufficient information should be provided to enable the reader to determine whether these are appropriate. Mean errors can mask systematic bias in the errors across the range of predicted HSUVs and it has been suggested that errors in subgroups such as EQ-5D range (EQ-5D \0, 0-0.25, 0.25-0.5, 0.5-0.75, 0.75-1) should also be reported [5] . Plots comparing observed and predicted mean HSUVs are particularly useful as they indicate how well the model fits the data and indicate any areas where the error in the predictions may be larger, such as more severe health states (see Fig. 5 in Hernandez Alava et al. [11] , where the observed and predicted EQ-5D scores are plotted across the range of observed HAQ scores). Providing further details on the size of the errors is recommended, reporting errors either by severity categories using a clinical variable or across the range of the PBM (see Table 5 in Hernandez Alava et al. [11] , which provides mean errors in the HSUVs predicted using the alternative functions subgrouped by HAQ score). Of prime importance is that the output clearly describes how to use the mapping algorithm to predict HSUVs in another dataset. Further validation of performance of mapping functions is recommended where this is possible, ideally in an independent sample where predicted and observed HSUVs can be compared to indicate the accuracy of the predictions. However, this is not routinely expected due to the frequent lack of suitable datasets.
Strengths and Limitations of Mapping
Mapping allows appropriate HSUVs to be generated for use in decision models including extrapolation, inclusion of important covariates that may affect the HSUVs and where they are completely missing. In the case where validated mapping functions based on appropriate data are available, then mapping can provide a quick and easy way to generate HSUVs. It also provides a pragmatic solution to generating the HSUVs required in a decision model where appropriate data is available.
However, mapping will introduce additional uncertainty to the analysis, and should be considered as a second-best solution compared with directly collected HSUVs [5] . Published mapping functions may not report all the recommended information that is required to judge whether or not the recommended mapping functions are appropriate for use. Furthermore, datasets that are used are often based on a pragmatic choice (e.g. an existing trial), which may be limited in application across other studies of interest, meaning that the accuracy of the mapped results may be reduced. In addition, many existing studies are limited in their sample size (e.g. if they are collected using an existing trial) and where larger datasets are available these are often general population datasets that have limited data for more severe states. Some studies have found that the size of the error increases for more severe states [18] , due to both a combination of limited data availability in these states and limitations of the models used to estimate the mapping functions. However, it has been found that this limitation may have limited impact on the accuracy of economic evaluations using mapped values as these focus on the differences in QALYs over time or across groups rather than the levels [14] .
The accuracy of mapping functions is also affected by the overlap between the target and explanatory variables, and explanatory variables that are clinical or from a CSM may have little or limited overlap with the target utility measure; for example, the overlap may be limited to only a subset of the dimensions of the preference-based measure. Some CSMs can also fail to capture all co-morbidities and side effects, and hence this will impact on the ability of the CSM to predict the target utility measure.
Summary
This article has outlined the mapping process when using either existing published or new mapping functions. It covers considerations relating to where the HSUVs will be used and how the mapping functions should be generated, including data requirements, regression methods/models. Common issues and existing recommendations are summarised together with a checklist for minimum reporting standards. Mapping is of increasing interest as it enables appropriate HSUVs to be estimated for use in decision models. It is important to ensure that good practice is followed as any mapping results will only be as appropriate and accurate as the method used to obtain them.
